Please upgrade your browser.
Clues about genetic alterations that may contribute to a rare form of kidney cancer have been discovered...
Diabetes mellitus is independently associated with an increased risk of mortality among clear cell renal cell carcinoma patients
Conflicting data exist regarding the interaction of diabetes mellitus (DM) with outcomes for patients with renal cell carcinoma (RCC).
Cancer simply may be here to stay.
Comprehensive molecular analysis is performed on 66 kidney chromophobe cases
Phase 1 Clinical Trial of Antibody-Drug Conjugate SGN-CD70A for Non-Hodgkin Lymphoma and Renal Cell Carcinoma
"CD70 is a very promising ADC antigen, which is highly expressed in both NHL and RCC, and has minimal expression in healthy tissues," said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development, at Seattle Genetics.
Improve patient care by participating in The West Cancer Center Tumor Boards or start your own case discussions.
For most cancer patients and their doctors, the most important things to know about a tumor are where it arose in the body and how much it has grown.
Clear cell urothelial carcinoma is exceedingly rare, with only nine clinical cases described in the literature.
Brain metastasis occurs in 3.9-24% of patients with renal cell carcinoma (RCC), with an average interval from nephrectomy to brain metastasis of 1 to 3 years.
Sunitinib was administered for 9 months, which led to complete response (CR)
|Powered by NeonCRM|